Broad-spectrum host-acting antivirals: identification and characterization of anti-HIV drugs
Hundreds of host factors related to viral infections like HIV, hepatitis C virus, dengue virus or West Nile virus have been identified. As many of these host factors are shared by different viruses, chemical blockade of key virus-associated cellular components may effectively act as broad-spectrum a...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis doctoral |
| Estado: | Versión publicada |
| Fecha de publicación: | 2015 |
| País: | España |
| Institución: | CBUC, CESCA |
| Repositorio: | TDR. Tesis Doctorales en Red |
| OAI Identifier: | oai:www.tdx.cat:10803/402212 |
| Acceso en línea: | http://hdl.handle.net/10803/402212 |
| Access Level: | acceso abierto |
| Palabra clave: | Broad-spectrum antivirals Host-actings antivirals HIV Soraphen A Ratjadone A VIH Antiiviral amplio aspectro Antiviral contra hospedador 578 |
| Sumario: | Hundreds of host factors related to viral infections like HIV, hepatitis C virus, dengue virus or West Nile virus have been identified. As many of these host factors are shared by different viruses, chemical blockade of key virus-associated cellular components may effectively act as broad-spectrum antiviral treatment. Broad-spectrum host-acting antivirals (HAAs) may reduce treatment complexity and costs, increase adherence to the therapy and may pose a higher barrier to develop resistance. In this thesis a high-throughput anti-HIV assay was used to screen for virus inhibitory effects of a library of secondary metabolites derived from myxobacteria. Compounds with high anti-HIV activity and low toxicity were classified as hits and two of them (ratjadone A and soraphen A) were selected for further analysis. The mechanism of HIV inhibition of both compounds is described here. The results presented in this thesis show that broad-spectrum HAAs are a feasible option for antiviral treatment and that the compounds identified can be further studied for hit-to-lead compound development. |
|---|